Curious to see the emissions of the organizations you buy from or invest in?
Book a demo for a pilot project
Book a demo for a pilot project
Argenx SE, a leading player in the pharmaceutical preparation manufacturing industry, is headquartered in the Netherlands and operates extensively across Europe and North America. Founded in 2008, the company has rapidly advanced in the biopharmaceutical sector, focusing on the development of innovative therapies for severe autoimmune diseases and cancer.
Argenx is renowned for its unique antibody-based treatments, particularly its flagship product, efgartigimod, which has shown promising results in clinical trials. The company’s commitment to scientific excellence and patient-centric solutions has positioned it as a notable contender in the global market. With a robust pipeline and strategic partnerships, Argenx continues to make significant strides in addressing unmet medical needs, solidifying its reputation as a pioneer in the field.
+19 vs industry average
Argenx’s score of 61 is higher than 68% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Pharmaceutical Preparation Manufacturing is among the least carbon-intensive industries
The Pharmaceutical Preparation Manufacturing industry has increased its overall emissions by 132% since 0
Scope 3 accounts for ••• of total emissions.
Argenx, a pharmaceutical preparation manufacturing company headquartered in the Netherlands, reported its latest carbon emissions for 2024. The company's total emissions for 2024 were approximately 231.77 million kg CO2e. This figure includes about 3.79 million kg CO2e from Scope 1 emissions, approximately 534,000 kg CO2e from Scope 2 (market-based), and around 227.45 million kg CO2e from Scope 3 emissions. Key contributors to Scope 3 emissions in 2024 included purchased goods and services (approximately 183.78 million kg CO2e) and upstream transportation and distribution (around 24.56 million kg CO2e).
In the preceding year, 2023, Argenx's total emissions were higher at approximately 433.35 million kg CO2e. This comprised about 378,000 kg CO2e from Scope 1, approximately 189,000 kg CO2e from Scope 2 (market-based), and roughly 432.79 million kg CO2e from Scope 3. Notably, purchased goods and services accounted for a significant portion of Scope 3 emissions in 2023, at approximately 378.96 million kg CO2e.
Argenx does not currently have publicly disclosed science-based targets or other formal climate reduction initiatives. Their performance data is directly reported by argenx SE.
No climate goals have been disclosed for Argenx yet.
See all scope 3 categories
Already have an account? Sign in now


PCAF scored Scope 1, 2 and 3 for 2M+ organizations, including private ones.
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn more